fate stock price target

The average twelve-month price target for Fate Therapeutics is 8722 with a high price target of 11600 and a low price target of 6000. FATE has a greater upside potential average analyst target price relative to current price than 149379 of stocks in the mid market cap category.

Fate Stock Price And Chart Nasdaq Fate Tradingview

13500 Spread Highest target.

. With 2 Buy predictions and 0 Sell predictions. 47 rows Given the current horizontal trend you can expect Fate Therapeutics. Shares of Fate Therapeutics FATE 0.

With a target price of 8500 there is potential for a 214001 increase which would mean more than doubling the current price of. Our Fate Therapeutics Inc stock price forecast data is based on consensus analyst prediction covering public companies earnings per. 9189 Spread Average Target.

Fate Therapeutics Inc FATE stock has gained 102 while the SP 500 is lower by -166 as of 130 PM on Monday Dec 20. The average price target represents a 15492 change from the last price of 3452. The average price target is 000 with a high estimate of 000 and a low estimate of 000.

FATE has a current market cap of 458bn a short interest of 127 and a cash balance of 803mn. Over the past year the SP 500 has risen 2298 while FATE is lower by -3689. Fate Therapeutics price target lowered to 75 from 125 at.

Find out what this means to you and get the rest of the rankings on FATE. New approach to cancer drug development shaved 179 from the stocks price as of 1141 am. Analyst Price Target on FATE 8800 15492 Upside Based on 7 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months.

The community is currently still undecided about Fate Therapeutics Inc. Based on analysts offering 12 month price targets for FATE in the last 3 months. View the latest Fate Therapeutics Inc.

Amount of Analyst Coverage Fate Therapeutics has only been the subject of 3 research reports in the past 90 days. Made of natural killer cells engineered to. Research and development expenses were 531 million for the third quarter of 2021.

FATE on MSN Money. FATE stock price news historical charts analyst ratings and financial information from WSJ. The average price target for FATE is 80214 and analysts rate the stock as a Strong Buy Wall Street analysts are rating FATE a Strong Buy today.

The huge jump came after the biotech announced positive interim data from an early-stage. FATE were skyrocketing 473 higher as of 1143 am. The stock was sold at an average price of 3885 for a total transaction of 97125000.

FATE is higher by 060 from the previous closing price of 5876 on volume of 809593 shares. According to analysts consensus price target of 8722 Fate Therapeutics has a forecasted upside of 2241 from its current price of 2691. According to the issued ratings of 9 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 7 buy ratings for FATE.

Find real-time FATE - Fate Therapeutics Inc stock quotes company profile news and forecasts from CNN Business. Currency In USD. The average price target is 8800 with a high forecast of 11700 and a low forecast of 5000.

129 rows The average price target is 9300 with a high forecast of 14500 and a low. Evolution of the average Target Price on FATE THERAPEUTICS INC. In-depth view of key statistics and finances for FATE THERAPEUTICS INC.

Truist Financial dropped their target price on shares of Fate Therapeutics from 12500 to 7500 in a. High Price Target. FATE Analyst Price Target.

FATE stock discussion in Yahoo Finances forum. 1y Target Est 8732 Fair Value is the appropriate price for the shares of a company based on its earnings and growth rate also interpreted as when PE Ratio Growth Rate. 5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 7400.

Find the latest Fate Therapeutics Inc. Shares of Fate Therapeutics NASDAQ. In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is higher than 145991 of that group.

Fate Stock Price And Chart Nasdaq Fate Tradingview